Additionally, glucocorticoids, commonly used as adjuvants in lung cancer therapy, promote gluconeogenesis in the liver, inhibit glucose uptake and utilization in peripheral tissues, enhance the action of hyperglycemic hormones (such as growth hormone, epinephrine, and glucagon), and may also damage islet cell function. This evidence concerns the gene GCG and lung carcinoma.